Discovery of Microbiome-based Biomarkers for Patients With Cancer Using Metagenomic Approach
Discovery of Microbiome-based Biomarkers for Patients With Cancer Using Metagenomic
Gustave Roussy, Cancer Campus, Grand Paris
1,100 participants
Jan 22, 2018
OBSERVATIONAL
Conditions
Summary
Multicentric prospective study with collection of biological samples as part of type II research
Eligibility
Inclusion Criteria3
- Patient with cancer who will start treatment anticancer (see cohorts).
- Patient information and signature of the consent form before any specific procedure for the study. The patient must be able and must be inclined to cooperate in the study procedures.
- Patient affiliated to a social security scheme or beneficiary of a similar scheme.
Exclusion Criteria2
- Pregnant or lactating woman
- Patient under guardianship or curatorship or deprived of liberty by a decision judicial or administrative or patient unable to give his consent.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
collection at baseline (or before the third injection), at the first evaluation (CT-scan), at ≥ 6 months after the first injection, at toxicity and at relapse, at 1 week after the end of antibiotics treatment
20 mL collection at baseline (or before the third injection), at the first evaluation (CT-scan), at ≥ 6 months after the first injection, at toxicity and at relapse, at 1 week after the end of antibiotics treatment
Locations(9)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04567446